MedCity News February 16, 2023
Marissa Plescia

Cognoa’s Canvas Dx product is authorized by the Food and Drug Administration and assists healthcare providers in diagnosing autism spectrum disorder for children ages 18 months through 72 months. Members of Health Transformation Alliance can now add Canvas Dx to their benefit plans.

The Health Transformation Alliance (HTA), a group of nearly 60 large employers, announced Thursday it is partnering with pediatric behavioral health company Cognoa for its diagnostic device for autism.

HTA is a cooperative of self-insured employers, including Walgreens, CocaCola, Verizon and American Express. Palo Alto, California-based Cognoa, meanwhile, is a developer of AI-based technologies for early diagnosis of children with developmental and behavioral health conditions. Its Canvas Dx product is authorized by the Food and Drug Administration...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Employer, Insurance, Medical Devices, Mental Health, Provider, Self-insured
Related Articles:
From MSSP ACOs to Employer Value: Translating Value-Based Principles to Self-Insured Plans
Legal Issues in Value-Based Care Contracts for Self-Insured Employers
Restoring Affordability to Employer Health Plans
Carrum Health Expands SUD Treatment Program to Include Nearly All Substances
Healthcare Benefit Trends Report: Employers Shift to More Independent Navigation, Embrace GLP-1 Drugs with Restrictions

Share Article